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Neurofolicullar hamartoma presenting as a rare adnexal 
neoplasm in association with basal cell carcinoma 
 
 
Abstract 
Background: Neurofollicular hamartoma (NFH) is characterized histopathologically by 
fascicles of spindle cells that laterally delimited by hyperplastic folliculosebaceous units. It 
usually appears on face, near the nose or nasolabial fold. It does not manifest true neural 
differentiation and recently the term spindle cell predominant trichodiscoma (SCPT) has 
been used instead.  
Case Presentation: We present a case of a 40-year-old male with co-incidence of NFH 
and basal cell carcinoma (BCC) that the mesenchymal components of NFH were similar to 
SCPT but these components highly expressed S-100 protein. We also discuss about the 
histological aspect of the neoplasia in this report and consider the findings of other reports 
in association with classification of NFH by means of cellular markers and morphological 
resemblance to other skin hamartomas. 
Conclusion: Neurofollicular hamartoma is a rare benign tumor that thought to represent 
the cellular end of a morphological spectrum with trichodiscoma. The morphological 
features and expression of S100 protein in neural element helped us to achieve the 
diagnosis of neurofollicular hamartoma. However, variable reports of S-100 protein 
expression in NFH are available and further studies are needed to determine the 
classification of this tumor.  
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Neurofollicular hamartoma (NFH) is a rare neoplasm that was first described by 
Barr and Goodman in 1989. It is characterized histopathologically by fascicles of spindle 
cells that are haphazardly arranged and laterally delimited by hyperplastic 
folliculosebaceous units. This neoplasm exhibits both epithelial and stromal components. 
The epithelial component consists of distorted hyperplastic pilosebaceous units, while the 
stroma reveals neuroid differentiation. It usually appears on face, especially near the nose 
or nasolabial fold (1, 2). Despite its name, it does not manifest true neural differentiation 
and recently the term spindle cell predominant trichodiscoma (SCPT) has been used 
instead. Adults are affected in the fourth or the fifth decades of life and there is no gender 
preponderance (3). Due to similarities of NFH to neural elements and high resemblance to 
trichodiscoma, and considering the observations in some reports, the precise classification 
of this neoplasm is controversial. We report a rare case of a middle-aged patient with two 
facial lesions who was primarily diagnosed with basal cell carcinoma but further 
pathological study revealed the co-incidence of neurofollicular hamartoma. We also 
discussed about the morphology and histology of this tumor and its similarity to other skin 
hamartomas. 
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Case Presentation 
A 40-year-old male presented with the appearance of 
skin lesions on his face during the past two months. Past 
medical history of diabetes mellitus was noted for him 
without any genetic disorder. On clinical examination, two 
skin-colored dome shaped firm masses were noted with each 
size of 10×5mm and 5×5mm, respectively. The larger lesion 
showed surface ulcerations. With suspicion of basal cell 
carcinoma (BCC) for both lesions, excisional biopsy was 
performed and sent for pathological study including 
hematoxylin and eosin (H&E) and immunohistochemical 
(IHC) staining for S-100, neuron specific enolase (NSE), 
smooth muscle actin (SMA), and desmin markers. 
Histopathological results confirmed the BCC, nodular type, 
for the larger one (figure 1).  
 
 
 
 
 
 
 
 
 
 
Figure 1. Hematoxylin and eosin (H&E) staining of the larger 
lesion showing basal cell carcinoma (BCC), nodular type 
H&E stained sections of smaller lesion showed epidermis 
with unremarkable changes. The dermis displayed a well 
circumscribed, non-encapsulated lesion composed of 
epithelial and mesenchymal components. The epithelial 
component consist of distorted and hyperplastic 
pilosebaceous units with prominent sebaceous glands (fig 2).  
 
 
 
 
 
 
 
 
 
 
Figure 2. Distorted and hyperplastic pilosebaceous units 
with prominent sebaceous glands. H&E staining of 
epithelial and mesenchymal components 
The mesenchymal component mainly showed myxoid 
and fibrillary appearance containing elongated and wavy 
spindle cells arranged in fascicles resembling neurofibroma 
(figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Myxoid and fibrillary appearance containing 
elongated and wavy spindle cells (H&E staining) 
 
Further immunohistochemical study for confirmation of 
neural mesenchymal stroma was done. Fibrillary 
mesenchymal componenets express S-100 marker (figure 4), 
while neuron specific enolase, smooth muscle actin, and 
desmin were negative (figure 5). Based on the results of 
H&E staining and IHC, the diagnosis of neurofollicular 
hamartoma was confirmed.  Neurofollicular hamartoma itself 
is a benign tumor and treatment was achieved by local 
excision. The BCC lesion was demarcated and small in size 
which was surgically removed without further topical 
treatment or radiotherapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Immunohistochemical staining, fibrillary 
mesenchymal components express S-100 marker 
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Figure 5. NSE and SMA, and desmin markers were 
negative in IHC staining of mesenchymal components 
 
 
Discussion 
Neurofollicular hamartoma as a rare benign tumor is 
thought to represent the cellular end of a morphological 
spectrum with trichodiscoma. The clinical differential 
diagnosis includes fibrous papule, basal cell carcinoma, and 
dermal nevus (3). NFH is the tumor with follicular 
differentiation that expresses diffuse CD34 stromal 
positivity, Bcl-2 on outermost basal cells, and CD10 on 
perifollicular and peritumoral stroma. It shares these features 
with basaloid follicular hamartomas (BFH) and vellus hair 
hamartoma (VHH) which have the same follicular growth 
pattern (4). A case report of neurofollicular hamartoma 
showed that these lesions could express strong and diffuse 
pattern of S-100 protein on spindled cells. Scattered 
positivity of spindle cells for monoclonal neuron specific 
enolase and synaptophysin was also noted (5). The 
pathologic study results in our patient demonstrated that the 
lesion had myxoid and fibrillary components with wavy 
spindle cells just as SCPT, but these components highly 
expressed S-100 marker along with it. Kutzner et al. stated 
that NFH is CD34-positive cellular trichodiscoma that 
contain fascicles of fibrocystic spindle cells. They noted that 
mesenchymal component of NFH consists of wavy nuclei 
with focal S-100 positivity without any sign of neural 
differentiation. They used the term spindle cell predominant 
trichodiscoma (SCPT) instead of neurofollicular hamartoma 
to describe precise morphological the entity. Differential 
diagnosis of NFH should include all fairly circumscribed 
superﬁcial cellular lesions composed of CD34 positive 
spindle cells. Despite clinicopathological resemblance of 
angiofibroma to NHF, angiofibroma shows a dense 
collagenous stroma with a diffuse scatter of single cells in 
conjunction with more capillary vessels (6). Kacerovska et 
al. reported a case of SCPT with a focal palisaded 
arrangement of stromal cell just like those seen in 
schwannoma, in which the stromal cells were positive for 
CD34 and negative for S-100 protein. The similarity of 
SCPT to peripheral nerve neoplasms was mentioned by 
illustrations (7).  
Basal cell carcinoma (BCC) is the most common 
cutaneous malignant neoplasm. It has slow growth pattern 
and rarely metastasize but a small proportion (less than 
0.5%) of this tumor is locally aggressive. Nests of uniform 
basaloid cells within the dermis that are often separated from 
the adjacent stroma by the thin clefts are apparent in H&E 
stained sections (8). The lesions in this patient were small 
with clear margins and they surgically removed with 
consideration of cosmetics. In this report (to our knowledge), 
we describe the first co-incidence of BCC and 
neurofollicular hamartoma. The morphological features of 
smaller lesion and also expression of S100 protein in neural 
element helped us to achieve the diagnosis of neurofollicular 
hamartoma. Based on variable reports of S-100 protein 
expression in NFH, as well as its similarity to peripheral 
nerve tumors, further studies are needed to determine the 
classification and differentiation of NFH. 
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